Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiff University

http://www.cf.ac.uk

Latest From Cardiff University

Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC

A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.

Clinical Trials Personalized Medicine

Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation

Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.

Deals Business Strategies

Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

Business Strategies Commercial

OncoTherics Ltd.

Cancers, even those that initially respond to treatment, can become resistant to chemotherapy and radiotherapy; one of the causes behind this is the hypoxia found in some tumors. OncoTherics Ltd. is tackling this by developing non-toxic prodrugs that are activated to potent anticancer drugs in hypoxic conditions, selectively targeting the hard-to-treat cancer cells but sparing healthy tissue.

BioPharmaceutical
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register